{"id":42186,"date":"2026-03-12T09:35:11","date_gmt":"2026-03-12T12:35:11","guid":{"rendered":"https:\/\/www.grupomedcof.com.br\/blog\/?p=42186"},"modified":"2026-03-12T09:35:14","modified_gmt":"2026-03-12T12:35:14","slug":"anvisa-aprova-cenobamato-para-epilepsia-resistente","status":"publish","type":"post","link":"https:\/\/www.grupomedcof.com.br\/blog\/anvisa-aprova-cenobamato-para-epilepsia-resistente\/","title":{"rendered":"Novo medicamento para epilepsia resistente a tratamento aprovado pela Anvisa"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_74 counter-hierarchy ez-toc-counter ez-toc-transparent ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Sum\u00e1rio<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Alternar tabela de conte\u00fado\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.grupomedcof.com.br\/blog\/anvisa-aprova-cenobamato-para-epilepsia-resistente\/#Novo_tratamento_para_epilepsia_resistente\" >Novo tratamento para epilepsia resistente<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.grupomedcof.com.br\/blog\/anvisa-aprova-cenobamato-para-epilepsia-resistente\/#Como_funciona_o_cenobamato\" >Como funciona o cenobamato<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.grupomedcof.com.br\/blog\/anvisa-aprova-cenobamato-para-epilepsia-resistente\/#O_que_muda_com_a_aprovacao\" >O que muda com a aprova\u00e7\u00e3o<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.grupomedcof.com.br\/blog\/anvisa-aprova-cenobamato-para-epilepsia-resistente\/#Acompanhe_as_principais_noticias_da_saude\" >Acompanhe as principais not\u00edcias da sa\u00fade!<\/a><\/li><\/ul><\/nav><\/div>\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"576\" src=\"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/03\/Blog-MedCof-2026-03-12T092930.613-1024x576.jpg\" alt=\"\" class=\"wp-image-42187\" srcset=\"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/03\/Blog-MedCof-2026-03-12T092930.613-1024x576.jpg 1024w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/03\/Blog-MedCof-2026-03-12T092930.613-300x169.jpg 300w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/03\/Blog-MedCof-2026-03-12T092930.613-768x432.jpg 768w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/03\/Blog-MedCof-2026-03-12T092930.613-1536x864.jpg 1536w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/03\/Blog-MedCof-2026-03-12T092930.613-747x420.jpg 747w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/03\/Blog-MedCof-2026-03-12T092930.613-150x84.jpg 150w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/03\/Blog-MedCof-2026-03-12T092930.613-696x392.jpg 696w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/03\/Blog-MedCof-2026-03-12T092930.613-1068x601.jpg 1068w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/03\/Blog-MedCof-2026-03-12T092930.613.jpg 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>A <strong>Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa)<\/strong> aprovou um novo medicamento para o tratamento de adultos com <strong>epilepsia resistente a tratamento.<\/strong> A decis\u00e3o foi publicada no <strong>Di\u00e1rio Oficial da Uni\u00e3o<\/strong> e representa mais uma alternativa terap\u00eautica para pacientes que n\u00e3o respondem adequadamente \u00e0s op\u00e7\u00f5es j\u00e1 dispon\u00edveis.<\/p>\n\n\n\n<p>O medicamento aprovado \u00e9 o <strong>cenobamato<\/strong>, comercializado com o nome <strong>Xcopri<\/strong>, da farmac\u00eautica <strong>Eurofarma<\/strong>. A autoriza\u00e7\u00e3o consta na <strong>Resolu\u00e7\u00e3o-RE n\u00ba 855, de 5 de mar\u00e7o de 2026<\/strong>, que trata do registro de novos medicamentos no pa\u00eds.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-novo-tratamento-para-epilepsia-resistente\"><span class=\"ez-toc-section\" id=\"Novo_tratamento_para_epilepsia_resistente\"><\/span><strong>Novo tratamento para epilepsia resistente<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>A<strong> epilepsia<\/strong> \u00e9 uma doen\u00e7a neurol\u00f3gica caracterizada por crises epil\u00e9pticas recorrentes, provocadas por descargas el\u00e9tricas anormais no c\u00e9rebro. Em parte dos pacientes, as crises podem persistir mesmo com o uso de medicamentos antiepil\u00e9pticos convencionais, um quadro conhecido como <strong>epilepsia resistente ou refrat\u00e1ria ao tratamento.<\/strong><\/p>\n\n\n\n<p>Para esses casos, <strong>novas op\u00e7\u00f5es terap\u00eauticas s\u00e3o consideradas fundamentais,<\/strong> pois ajudam a reduzir a frequ\u00eancia e a intensidade das crises e podem melhorar significativamente a qualidade de vida dos pacientes.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.grupomedcof.com.br\/cofletters\/?clientId=&amp;utm_campaign=newsletter&amp;utm_medium=banner&amp;utm_source=blog&amp;utm_content=inscricao#https:\/\/www.grupomedcof.com.br\/blog\/\" target=\"_blank\" rel=\" noreferrer noopener\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"320\" src=\"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2025\/11\/Banner-MedCof-Plus-2200x460-11-1343x420-1-1024x320.png\" alt=\"\" class=\"wp-image-39227\" srcset=\"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2025\/11\/Banner-MedCof-Plus-2200x460-11-1343x420-1-1024x320.png 1024w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2025\/11\/Banner-MedCof-Plus-2200x460-11-1343x420-1-300x94.png 300w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2025\/11\/Banner-MedCof-Plus-2200x460-11-1343x420-1-768x240.png 768w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2025\/11\/Banner-MedCof-Plus-2200x460-11-1343x420-1-150x47.png 150w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2025\/11\/Banner-MedCof-Plus-2200x460-11-1343x420-1-696x218.png 696w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2025\/11\/Banner-MedCof-Plus-2200x460-11-1343x420-1-1068x334.png 1068w, https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2025\/11\/Banner-MedCof-Plus-2200x460-11-1343x420-1.png 1343w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-como-funciona-o-cenobamato\"><span class=\"ez-toc-section\" id=\"Como_funciona_o_cenobamato\"><\/span><strong>Como funciona o cenobamato<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>O <strong>cenobamato<\/strong> \u00e9 um medicamento <strong>anticonvulsivante<\/strong> indicado como terapia adjuvante para adultos com crises epil\u00e9pticas focais. Ele atua <strong>modulando canais de s\u00f3dio dependentes de voltagem<\/strong> e<strong> aumentando a atividade do neurotransmissor inibit\u00f3rio GABA<\/strong>, mecanismos que ajudam a reduzir a hiperexcitabilidade neuronal respons\u00e1vel pelas crises.<\/p>\n\n\n\n<p>O medicamento ser\u00e1 disponibilizado em diferentes concentra\u00e7\u00f5es e apresenta\u00e7\u00f5es, permitindo o ajuste gradual da dose conforme orienta\u00e7\u00e3o m\u00e9dica.<\/p>\n\n\n\n<p>De acordo com a <strong>resolu\u00e7\u00e3o publicada pela Anvisa<\/strong>, o registro contempla comprimidos com diversas dosagens, incluindo apresenta\u00e7\u00f5es de <strong>12,5 mg, 50 mg, 100 mg e 200 mg<\/strong>, al\u00e9m de combina\u00e7\u00f5es utilizadas na titula\u00e7\u00e3o inicial do tratamento.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-o-que-muda-com-a-aprovacao\"><span class=\"ez-toc-section\" id=\"O_que_muda_com_a_aprovacao\"><\/span><strong>O que muda com a aprova\u00e7\u00e3o<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Com o registro sanit\u00e1rio concedido pela Anvisa, o medicamento passa a estar<strong> autorizado para comercializa\u00e7\u00e3o no Brasil.<\/strong> No entanto, a disponibilidade para pacientes depende de etapas adicionais, como <strong>defini\u00e7\u00e3o de pre\u00e7o pela C\u00e2mara de Regula\u00e7\u00e3o do Mercado de Medicamentos (CMED)<\/strong> e posterior <strong>distribui\u00e7\u00e3o no mercado.<\/strong><\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/03\/RESOLUCAO-RE-no-855-DE-05-DE-MARCO-DE-2026-RESOLUCAO-RE-no-855-DE-05-DE-MARCO-DE-2026-DOU-Imprensa-Nacional.pdf\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>Resolu\u00e7\u00e3o-RE n\u00ba 855<\/strong><\/a><\/div>\n<\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-acompanhe-as-principais-noticias-da-saude\"><span class=\"ez-toc-section\" id=\"Acompanhe_as_principais_noticias_da_saude\"><\/span><strong>Acompanhe as principais not\u00edcias da sa\u00fade!<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p id=\"h-\">Quer se manter atualizado sobre as principais mudan\u00e7as no SUS e na&nbsp;<a href=\"https:\/\/www.grupomedcof.com.br\/home\/?utm_source=google&amp;utm_medium=cpc&amp;utm_campaign=google-cpc-residencia-medica-r-um-ongoing-branding-src-maxclicks&amp;gad_source=1&amp;gad_campaignid=18911950485&amp;gbraid=0AAAAACaXGt3PefrzIOCMt-B8iQ5jCY5X6&amp;gclid=Cj0KCQiA8KTNBhD_ARIsAOvp6DILkQNeB3iJw5A46LpaYywt3lxlTXGEWcp7kakjhnyNzIXN_MW7v54aAvuNEALw_wcB\" target=\"_blank\" rel=\"noreferrer noopener\">pr\u00e1tica m\u00e9dica<\/a>? Continue acompanhando o&nbsp;<strong>Blog MedCof<\/strong>&nbsp;para mais conte\u00fados sobre sa\u00fade, carreira m\u00e9dica e resid\u00eancia!<\/p>\n\n\n\n<figure class=\"wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<div class=\"youtube-embed\" data-video_id=\"Q5whMaiXm3k\"><iframe loading=\"lazy\" title=\"20 mil quest\u00f5es: o m\u00e9todo que levou \u00e0 aprova\u00e7\u00e3o em 9 resid\u00eancias | #PapodeAprovado\" width=\"696\" height=\"392\" src=\"https:\/\/www.youtube.com\/embed\/Q5whMaiXm3k?feature=oembed&#038;enablejsapi=1\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/div>\n<\/div><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>A Anvisa aprovou o medicamento cenobamato (Xcopri) para tratamento de adultos com epilepsia resistente. Saiba como funciona a nova terapia.<\/p>\n","protected":false},"author":18,"featured_media":42187,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[240],"tags":[1685,3608,3033],"ppma_author":[3611],"class_list":{"0":"post-42186","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-noticias","8":"tag-anvisa","9":"tag-cenobamato","10":"tag-epilepsia"},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.3 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novo medicamento para epilepsia resistente a tratamento aprovado pela Anvisa - Blog de Medcof: conte\u00fados, editais, revalida e mais!<\/title>\n<meta name=\"description\" content=\"A Anvisa aprovou o medicamento cenobamato (Xcopri) para tratamento de adultos com epilepsia resistente. Saiba como funciona a nova terapia.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.grupomedcof.com.br\/blog\/anvisa-aprova-cenobamato-para-epilepsia-resistente\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo medicamento para epilepsia resistente a tratamento aprovado pela Anvisa\" \/>\n<meta property=\"og:description\" content=\"A Anvisa aprovou o medicamento cenobamato (Xcopri) para tratamento de adultos com epilepsia resistente. Saiba como funciona a nova terapia.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.grupomedcof.com.br\/blog\/anvisa-aprova-cenobamato-para-epilepsia-resistente\/\" \/>\n<meta property=\"og:site_name\" content=\"Blog de Medcof: conte\u00fados, editais, revalida e mais!\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/MedCofQbank\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-12T12:35:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-12T12:35:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/03\/Blog-MedCof-2026-03-12T092930.613.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Leila Menzel\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Leila Menzel\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/anvisa-aprova-cenobamato-para-epilepsia-resistente\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/anvisa-aprova-cenobamato-para-epilepsia-resistente\\\/\"},\"author\":{\"name\":\"Leila Menzel\",\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/#\\\/schema\\\/person\\\/2a5527209c17e7eb35bd6a4ebd5c7956\"},\"headline\":\"Novo medicamento para epilepsia resistente a tratamento aprovado pela Anvisa\",\"datePublished\":\"2026-03-12T12:35:11+00:00\",\"dateModified\":\"2026-03-12T12:35:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/anvisa-aprova-cenobamato-para-epilepsia-resistente\\\/\"},\"wordCount\":419,\"publisher\":{\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/anvisa-aprova-cenobamato-para-epilepsia-resistente\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Blog-MedCof-2026-03-12T092930.613.jpg\",\"keywords\":[\"Anvisa\",\"Cenobamato\",\"Epilepsia\"],\"articleSection\":[\"Not\u00edcias\"],\"inLanguage\":\"pt-BR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/anvisa-aprova-cenobamato-para-epilepsia-resistente\\\/\",\"url\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/anvisa-aprova-cenobamato-para-epilepsia-resistente\\\/\",\"name\":\"Novo medicamento para epilepsia resistente a tratamento aprovado pela Anvisa - Blog de Medcof: conte\u00fados, editais, revalida e mais!\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/anvisa-aprova-cenobamato-para-epilepsia-resistente\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/anvisa-aprova-cenobamato-para-epilepsia-resistente\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Blog-MedCof-2026-03-12T092930.613.jpg\",\"datePublished\":\"2026-03-12T12:35:11+00:00\",\"dateModified\":\"2026-03-12T12:35:14+00:00\",\"description\":\"A Anvisa aprovou o medicamento cenobamato (Xcopri) para tratamento de adultos com epilepsia resistente. Saiba como funciona a nova terapia.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/anvisa-aprova-cenobamato-para-epilepsia-resistente\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/anvisa-aprova-cenobamato-para-epilepsia-resistente\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/anvisa-aprova-cenobamato-para-epilepsia-resistente\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Blog-MedCof-2026-03-12T092930.613.jpg\",\"contentUrl\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Blog-MedCof-2026-03-12T092930.613.jpg\",\"width\":1920,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/anvisa-aprova-cenobamato-para-epilepsia-resistente\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo medicamento para epilepsia resistente a tratamento aprovado pela Anvisa\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/\",\"name\":\"Blog de Medcof: conte\u00fados, editais, revalida e mais!\",\"description\":\"Acesso o blog de MedCof! Seu portal de conte\u00fados sobre resid\u00eancia m\u00e9dica, an\u00e1lise e editais e muito mais. Clique e confira!\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/#organization\"},\"alternateName\":\"Blog de Medcof: conte\u00fados, editais, revalida e mais!\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/#organization\",\"name\":\"Grupo MedCof\",\"url\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/logo-medcof.png\",\"contentUrl\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/logo-medcof.png\",\"width\":768,\"height\":269,\"caption\":\"Grupo MedCof\"},\"image\":{\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/MedCofQbank\\\/\",\"https:\\\/\\\/www.instagram.com\\\/grupomedcof\\\/\",\"https:\\\/\\\/br.linkedin.com\\\/company\\\/medcof\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCdHMuOHKICxcHwecxN8P-AA\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/#\\\/schema\\\/person\\\/2a5527209c17e7eb35bd6a4ebd5c7956\",\"name\":\"Leila Menzel\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/cropped-cropped-cropped-logo-96x96.png15459389df217b605b4f0cce419ac81a\",\"url\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/cropped-cropped-cropped-logo-96x96.png\",\"contentUrl\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/cropped-cropped-cropped-logo-96x96.png\",\"caption\":\"Leila Menzel\"},\"description\":\"Estudante do 6\u00b0 semestre de jornalismo, amo e escrevo poesias e viajo em livros de romances clich\u00eas.\",\"url\":\"https:\\\/\\\/www.grupomedcof.com.br\\\/blog\\\/author\\\/leila\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo medicamento para epilepsia resistente a tratamento aprovado pela Anvisa - Blog de Medcof: conte\u00fados, editais, revalida e mais!","description":"A Anvisa aprovou o medicamento cenobamato (Xcopri) para tratamento de adultos com epilepsia resistente. Saiba como funciona a nova terapia.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.grupomedcof.com.br\/blog\/anvisa-aprova-cenobamato-para-epilepsia-resistente\/","og_locale":"pt_BR","og_type":"article","og_title":"Novo medicamento para epilepsia resistente a tratamento aprovado pela Anvisa","og_description":"A Anvisa aprovou o medicamento cenobamato (Xcopri) para tratamento de adultos com epilepsia resistente. Saiba como funciona a nova terapia.","og_url":"https:\/\/www.grupomedcof.com.br\/blog\/anvisa-aprova-cenobamato-para-epilepsia-resistente\/","og_site_name":"Blog de Medcof: conte\u00fados, editais, revalida e mais!","article_publisher":"https:\/\/www.facebook.com\/MedCofQbank\/","article_published_time":"2026-03-12T12:35:11+00:00","article_modified_time":"2026-03-12T12:35:14+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/03\/Blog-MedCof-2026-03-12T092930.613.jpg","type":"image\/jpeg"}],"author":"Leila Menzel","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Leila Menzel","Est. tempo de leitura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.grupomedcof.com.br\/blog\/anvisa-aprova-cenobamato-para-epilepsia-resistente\/#article","isPartOf":{"@id":"https:\/\/www.grupomedcof.com.br\/blog\/anvisa-aprova-cenobamato-para-epilepsia-resistente\/"},"author":{"name":"Leila Menzel","@id":"https:\/\/www.grupomedcof.com.br\/blog\/#\/schema\/person\/2a5527209c17e7eb35bd6a4ebd5c7956"},"headline":"Novo medicamento para epilepsia resistente a tratamento aprovado pela Anvisa","datePublished":"2026-03-12T12:35:11+00:00","dateModified":"2026-03-12T12:35:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.grupomedcof.com.br\/blog\/anvisa-aprova-cenobamato-para-epilepsia-resistente\/"},"wordCount":419,"publisher":{"@id":"https:\/\/www.grupomedcof.com.br\/blog\/#organization"},"image":{"@id":"https:\/\/www.grupomedcof.com.br\/blog\/anvisa-aprova-cenobamato-para-epilepsia-resistente\/#primaryimage"},"thumbnailUrl":"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/03\/Blog-MedCof-2026-03-12T092930.613.jpg","keywords":["Anvisa","Cenobamato","Epilepsia"],"articleSection":["Not\u00edcias"],"inLanguage":"pt-BR"},{"@type":"WebPage","@id":"https:\/\/www.grupomedcof.com.br\/blog\/anvisa-aprova-cenobamato-para-epilepsia-resistente\/","url":"https:\/\/www.grupomedcof.com.br\/blog\/anvisa-aprova-cenobamato-para-epilepsia-resistente\/","name":"Novo medicamento para epilepsia resistente a tratamento aprovado pela Anvisa - Blog de Medcof: conte\u00fados, editais, revalida e mais!","isPartOf":{"@id":"https:\/\/www.grupomedcof.com.br\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.grupomedcof.com.br\/blog\/anvisa-aprova-cenobamato-para-epilepsia-resistente\/#primaryimage"},"image":{"@id":"https:\/\/www.grupomedcof.com.br\/blog\/anvisa-aprova-cenobamato-para-epilepsia-resistente\/#primaryimage"},"thumbnailUrl":"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/03\/Blog-MedCof-2026-03-12T092930.613.jpg","datePublished":"2026-03-12T12:35:11+00:00","dateModified":"2026-03-12T12:35:14+00:00","description":"A Anvisa aprovou o medicamento cenobamato (Xcopri) para tratamento de adultos com epilepsia resistente. Saiba como funciona a nova terapia.","breadcrumb":{"@id":"https:\/\/www.grupomedcof.com.br\/blog\/anvisa-aprova-cenobamato-para-epilepsia-resistente\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.grupomedcof.com.br\/blog\/anvisa-aprova-cenobamato-para-epilepsia-resistente\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/www.grupomedcof.com.br\/blog\/anvisa-aprova-cenobamato-para-epilepsia-resistente\/#primaryimage","url":"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/03\/Blog-MedCof-2026-03-12T092930.613.jpg","contentUrl":"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2026\/03\/Blog-MedCof-2026-03-12T092930.613.jpg","width":1920,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/www.grupomedcof.com.br\/blog\/anvisa-aprova-cenobamato-para-epilepsia-resistente\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/www.grupomedcof.com.br\/blog\/"},{"@type":"ListItem","position":2,"name":"Novo medicamento para epilepsia resistente a tratamento aprovado pela Anvisa"}]},{"@type":"WebSite","@id":"https:\/\/www.grupomedcof.com.br\/blog\/#website","url":"https:\/\/www.grupomedcof.com.br\/blog\/","name":"Blog de Medcof: conte\u00fados, editais, revalida e mais!","description":"Acesso o blog de MedCof! Seu portal de conte\u00fados sobre resid\u00eancia m\u00e9dica, an\u00e1lise e editais e muito mais. Clique e confira!","publisher":{"@id":"https:\/\/www.grupomedcof.com.br\/blog\/#organization"},"alternateName":"Blog de Medcof: conte\u00fados, editais, revalida e mais!","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.grupomedcof.com.br\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/www.grupomedcof.com.br\/blog\/#organization","name":"Grupo MedCof","url":"https:\/\/www.grupomedcof.com.br\/blog\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/www.grupomedcof.com.br\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2022\/01\/logo-medcof.png","contentUrl":"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2022\/01\/logo-medcof.png","width":768,"height":269,"caption":"Grupo MedCof"},"image":{"@id":"https:\/\/www.grupomedcof.com.br\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/MedCofQbank\/","https:\/\/www.instagram.com\/grupomedcof\/","https:\/\/br.linkedin.com\/company\/medcof","https:\/\/www.youtube.com\/channel\/UCdHMuOHKICxcHwecxN8P-AA"]},{"@type":"Person","@id":"https:\/\/www.grupomedcof.com.br\/blog\/#\/schema\/person\/2a5527209c17e7eb35bd6a4ebd5c7956","name":"Leila Menzel","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2023\/04\/cropped-cropped-cropped-logo-96x96.png15459389df217b605b4f0cce419ac81a","url":"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2023\/04\/cropped-cropped-cropped-logo-96x96.png","contentUrl":"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2023\/04\/cropped-cropped-cropped-logo-96x96.png","caption":"Leila Menzel"},"description":"Estudante do 6\u00b0 semestre de jornalismo, amo e escrevo poesias e viajo em livros de romances clich\u00eas.","url":"https:\/\/www.grupomedcof.com.br\/blog\/author\/leila\/"}]}},"authors":[{"term_id":3611,"user_id":18,"is_guest":0,"slug":"leila","display_name":"Leila Menzel","avatar_url":"https:\/\/www.grupomedcof.com.br\/blog\/wp-content\/uploads\/2023\/04\/cropped-cropped-cropped-logo-96x96.png","0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/www.grupomedcof.com.br\/blog\/wp-json\/wp\/v2\/posts\/42186","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.grupomedcof.com.br\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.grupomedcof.com.br\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.grupomedcof.com.br\/blog\/wp-json\/wp\/v2\/users\/18"}],"replies":[{"embeddable":true,"href":"https:\/\/www.grupomedcof.com.br\/blog\/wp-json\/wp\/v2\/comments?post=42186"}],"version-history":[{"count":1,"href":"https:\/\/www.grupomedcof.com.br\/blog\/wp-json\/wp\/v2\/posts\/42186\/revisions"}],"predecessor-version":[{"id":42189,"href":"https:\/\/www.grupomedcof.com.br\/blog\/wp-json\/wp\/v2\/posts\/42186\/revisions\/42189"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.grupomedcof.com.br\/blog\/wp-json\/wp\/v2\/media\/42187"}],"wp:attachment":[{"href":"https:\/\/www.grupomedcof.com.br\/blog\/wp-json\/wp\/v2\/media?parent=42186"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.grupomedcof.com.br\/blog\/wp-json\/wp\/v2\/categories?post=42186"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.grupomedcof.com.br\/blog\/wp-json\/wp\/v2\/tags?post=42186"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.grupomedcof.com.br\/blog\/wp-json\/wp\/v2\/ppma_author?post=42186"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}